James G. Krueger, MD, PhD, is the newest President of the American Skin Association (ASA).
He is the Head of the Laboratory for Investigative Dermatology at the Rockefeller University, Co-director of the Center for Clinical and Translational Science at the Rockefeller University Hospital, and Chief Executive Officer of the Rockefeller University Hospital in New York City.
“I am excited to welcome our new President and look forward to working closely with Jim. His 40 years of pioneering research and experience in the field of dermatology will be a tremendous asset to our organization,” says Howard P. Milstein, Chairman of ASA, in a news release.
Dr. Krueger’s research group at Rockefeller was the first to conduct clinical trials with specific, targeted immune antagonists in psoriasis; this work established that elimination of pathogenic T cells from skin lesions could reverse the full pathological phenotype of psoriasis. Since then, his group has used immune-based therapeutics to dissect inflammatory pathways in psoriasis and to conduct parallel pharmacogenomic studies that define mechanisms of targeted therapeutics in human populations. A more recent focus has been the definition of new inflammatory pathways as well as new types of inflammatory cells in psoriasis lesions that are now being targeted with new biologic drugs.
“I would like to take this opportunity to thank our immediate past President, who will now serve as President Emeritus, Dr. David Norris. David’s dedication to ASA over the last three decades has been inspiring,” adds Milstein.
In addition, ASA announced that Alexa B. Kimball, MD, MPH, is its newest board member. Dr. Kimball is CEO and President of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center in Boston, MA.
